For a 300 mg single-core tablet, wet granulation is selected when irbesartan is present at more than 25% w/w. Micronized irbesartan has low bulk density and high cohesion. These properties can destabilize the compression feed frame. The core uses irbesartan at 40–45% w/w. Lactose monohydrate is used at 25–30% w/w. Microcrystalline cellulose PH102 is used at 15–20% w/w. Croscarmellose sodium is used at 2–4% w/w. Povidone K30 is used at 3–5% w/w. Colloidal silicon dioxide is used at 0.5–1.0% w/w. Magnesium stearate is used at 0.5–1.0% w/w. Purified water is added at 35–45% w/w of dry powder mass. The wet mass endpoint is LOD 2.5–3.5% w/w. The wet mass is passed through a mill with a 1.5 mm screen. It is dried in a fluid-bed dryer with inlet air at 60–65 °C. Drying continues until LOD is ≤ 2.0% w/w. The granules are sized through a 1.0 mm screen. The dried granule should have a Carr index below 25. Its D50 should be 150–300 μm. Both values are monitored to prevent feed-frame segregation.

Compression is performed on a rotary tablet press. The tooling is 10.0 mm round concave. Target hardness is 80–120 N. Friability is ≤ 1.0% after 100 revolutions per USP <1031>. Compaction force above 25 kN can suppress capping. But hardness may exceed 150 N. This can reduce aqueous film-coat adhesion. Magnesium stearate should not exceed 1.0% w/w. Lubricated blend time should stay below 5 min. Longer mixing can reduce dissolution. The lubricant shears onto granule surfaces. Dissolution is tested per USP <711>. Apparatus 2 is used at 50 rpm in 900 mL of 0.1 M hydrochloric acid. The acceptance criterion is Q = 80% at 30 min. Content uniformity follows USP <905> with acceptance value ≤ 15.0. Film coating is applied in a perforated pan at 12–15% w/w solids. Target weight gain is 2.5–3.5% w/w.

Transfer and containment require attention because milled irbesartan granule can adhere to hopper walls under low humidity. If the processing suite is kept below 30% RH, static charge increases and feed frame hold-up increases. Die fill variation can then exceed 2.5%. A humidification step to 40–50% RH or addition of 0.5% w/w colloidal silicon dioxide controls static. Clean-in-place of the hopper and feed frame between batches follows 21 CFR 211.67. Cross-contamination limits are derived from health-based exposure limits. Cleaning validation is batch-specific and risk-based.

Why Capsule Filling after Direct Blending Fails at Rotary Encapsulation Speeds?

Encapsulation of irbesartan after direct blending is constrained by poor flow. On a dosator machine running at 60,000 capsules/h, bulk density below 0.40 g/mL can generate fill-weight RSD above 4.0%. This exceeds the in-process limit. Roller compaction is inserted before encapsulation. Roll pressure is 4–8 kN/cm. The ribbon is milled through a 0.8 mm screen. The densified granule reaches bulk density 0.55–0.65 g/mL. Its D50 is 200–400 μm. Fill-weight RSD is then below 2.0%. A roller-compacted capsule formulation contains irbesartan at 35–40% w/w. Lactose monohydrate is used at 20–25% w/w. Microcrystalline cellulose is used at 25–30% w/w. Croscarmellose sodium is used at 2–3% w/w. Colloidal silicon dioxide is used at 0.5–0.75% w/w. Magnesium stearate is used at 0.5–0.75% w/w.

Hard gelatin capsule size 0 or 00 is chosen by fill weight. The densified granule fills 400–480 mg into a size 0 shell under standard tamping settings. Capsule strengths of 75 mg and 150 mg are achieved by adjusting fill weight. Dissolution is measured per USP <711>. Apparatus 2 operates at 50 rpm in 900 mL of 0.1 M hydrochloric acid. A shell-opening lag of 1–2 min may occur at 37 °C. Q = 80% at 45 min is applied when the lag is validated. The capsule product must pass USP <905> content uniformity. It must also meet ICH Q3D(R2) elemental limits. Capsule shells with residual peroxide above 0.1 meq/kg require oxidation control. Without this control, assay and dissolution drift can occur at 40 °C/75% RH.

Sachet and dry suspension manufacturing diverges from solid unit dose production. The granule must disperse in water within 60 s. It must remain uniformly suspended for 5 min while a dose is withdrawn. Fluid-bed top-spray granulation is preferred. It produces porous low-density granules. D50 is 150–250 μm. Granule friability is low. A sugar-free dispersible sachet formulation contains irbesartan at 3–6% w/w. Mannitol or xylitol is used at 70–80% w/w. Crospovidone is used at 2–5% w/w. Colloidal silicon dioxide is used at 0.5–1.0% w/w. Xanthan gum is used at 0.3–0.8% w/w. The API is first dissolved or partially ionized in granulating fluid at pH 9.0–11.0. Trometamol or sodium hydroxide adjusts pH. The alkaline solution is sprayed at 10–15 g/min per kg of bed mass. Inlet air temperature is 50–60 °C. Recrystallization in the nozzle or filter bag must be prevented. It can reduce yield and alter granule D50.

After drying to LOD ≤ 2.0% w/w, the granule is screened through 0.5 mm. It is filled into sachets on a vertical form-fill-seal machine. Seal temperature is 140–160 °C. Fill-weight RSD is ≤ 2.0%. Reconstitution is performed in 200 mL of water at 20 °C. Manual swirling lasts 60 s. The suspension is sampled without sedimentation. If xanthan gum hydration is incomplete, initial viscosity remains below 50 mPa·s. Irbesartan particles settle before dose withdrawal. Reconstituted suspension pH is controlled between 6.5 and 9.0. This balances API solubility and oral tolerance. Release tests include USP <905> for unit-dose powder uniformity. Residual solvents are tested per USP <467>. Elemental impurities are tested per ICH Q3D(R2). The finished product specification includes reconstitution time and pourability. Conventional tablet disintegration is not applied.

Irbesartan-Hydrochlorothiazide Tablet Cores Are Not Simple Blends

Fixed-dose combination cores containing hydrochlorothiazide fail when the two APIs are simple dry-blended. Hydrochlorothiazide particles are denser and more free-flowing than micronized irbesartan. The blend can segregate. Assay RSD can exceed 6.0% from beginning to end of the compression run. This violates USP <905>. A preferred production route is wet granulation of irbesartan with major diluents. The dried granule is milled. Extragranular hydrochlorothiazide is added at 12.5 mg or 25 mg per tablet. Croscarmellose sodium and magnesium stearate are then added. The final core contains irbesartan at 20–45% w/w. Hydrochlorothiazide is at 2–5% w/w. Lactose monohydrate is at 20–30% w/w. Microcrystalline cellulose is at 15–25% w/w. Croscarmellose sodium is at 2–4% w/w. Magnesium stearate is at 0.5–1.0% w/w.

Commercial strengths are 150 mg/12.5 mg, 300 mg/12.5 mg, and 300 mg/25 mg. The 300 mg/25 mg strength has a core mass near 700–750 mg. Oval or capsule-shaped tooling is used. This reduces friability and improves die filling. The film-coating system contains hypromellose, polyethylene glycol, and titanium dioxide. Target weight gain is 2.5–3.5% w/w. Dissolution testing uses USP <711> Apparatus 2 at 50 rpm in 900 mL of 0.1 M hydrochloric acid. Both actives are quantitated by stability-indicating HPLC. Q = 80% at 30 min is commonly applied. Core hardness above 120 N can retard hydrochlorothiazide release. In-process hardness is held at 80–110 N. Release includes related substances by the compendial method. Residual solvents are tested per USP <467>. Elemental impurities are tested per USP <232>/<233>. Content uniformity is tested per USP <905>.

If Parenteral Administration Is Required, pH and Cosolvent Selection Dictate Sterility Strategy

Injectable irbesartan is not listed in any major pharmacopoeial finished-product monograph, and no approved parenteral product is currently marketed in the US or EU. When a parenteral dose is required for preclinical efficacy, toxicology, or comparator dosing, the formulator confronts the low aqueous solubility of irbesartan below pH 7.0. A simple saline or phosphate-buffered vehicle cannot achieve a concentration of 1.0 mg/mL or greater without ionisation or cosolvency. The most direct route is pH adjustment to 9.0–11.0, where the tetrazole proton is abstracted and solubility increases. However, the resulting pH is above the 9.0 limit generally considered acceptable for intramuscular or subcutaneous injection. Local irritation is a known risk. Parenteral development therefore concentrates on reducing pH to 8.0–9.0 with cosolvents or cyclodextrin complexation. A vehicle containing PEG 400, propylene glycol, and water in nonaqueous fractions above 40% v/v may cause haemolysis. It may also be incompatible with sterile filtration through 0.22 μm PVDF when the solvent system attacks the filter housing.

Published data for irbesartan–hydroxypropyl-β-cyclodextrin complexation are limited, but molar ratios from 1:5 to 1:20 have been used in solubility screening. The resulting formulation can reduce the pH required for clear solution and permit sterile filtration. Sterilisation by autoclaving at 121 °C for 15 min cannot be assumed. Forced-degradation studies per ICH Q1A(R2) may show pH-dependent hydrolysis of the tetrazole ring or discolouration. If terminal sterilisation is not qualified, the batch is filtered through 0.45 μm and 0.22 μm sterile filters and filled under aseptic conditions. Each batch is released for assay, related substances, pH, osmolality, particulate matter per USP <788>, bacterial endotoxins per USP <85>, and sterility per USP <71>. Particulate matter limits for small-volume injections are ≤ 6000 particles ≥ 10 μm and ≤ 600 particles ≥ 25 μm per container. Elemental impurities must meet ICH Q3D(R2) parenteral exposure limits.

For injectable application, no pharmacopoeial monograph constrains the formulator. A risk assessment is required to justify the use of antioxidants, preservatives, and buffer salts in a parenteral product. Sodium metabisulfite above 0.1% w/v can change the degradation profile. The batch-specific formulation must be placed in Type I borosilicate vials with siliconized chlorobutyl stoppers. Extractable and leachable testing is performed per USP <1663> and USP <1664>. For short-term clinical trial material, stability studies per ICH Q1A(R2) and analytical validation per ICH Q2(R2) are required. The absence of a compendial parenteral monograph means every batch is governed by an approved site specification. Safety margins must be established from toxicology and local tolerance data. Published data for this specific configuration is limited, so each new vehicle requires screening before use in humans.